Disseminated intravascular coagulation associated with granulocyte colony-stimulating factor therapy in a child with human immunodeficiency virus infection

1995 ◽  
Vol 126 (5) ◽  
pp. 749-752 ◽  
Author(s):  
Brigitta U. Mueller ◽  
Richard Burt ◽  
Leslie Gulick ◽  
Freda Jacobsen ◽  
Philip A. Pizzo ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Disseminated Intravascular Coagulation ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Intravascular Coagulation ◽  
Immunodeficiency Virus ◽  
Factor Therapy ◽  
Stimulating Factor

Granulocyte-Colony Stimulating Factor and Erythropoietin Therapy in Children with Human Immunodeficiency Virus Infection

1996 ◽  
Vol 24 (1) ◽  
pp. 115-121 ◽  
Author(s):  
G V Zuccotti ◽  
A Plebani ◽  
G Biasucci ◽  
M Clerici-Schoeller ◽  
G Banderali ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Side Effects ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Hiv Infection ◽  
Blood Transfusions ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Immunodeficiency Virus ◽  
Stimulating Factor

To determine whether granulocyte-colony stimulating factor and erythropoietin are effective in the therapy of neutropenia and anaemia related to human immunodeficiency virus (HIV) infection and to anti-retroviral agents, we recruited 11 HIV-infected children (mean age 4 years 10 months). All the children were given granulocyte-colony stimulating factor at a dosage of 5 μ-g/kg twice or three times a week while erythropoietin was administered additionally to three patients at a dosage of 50 U/kg twice a week. Both agents were administered subcutaneously for at least 4 months. Leukocyte and neutrophil counts significantly increased during the treatment (after 1 month, P = 0.003 and P = 0.009, respectively). Erythropoietin prevented blood transfusions and increased haemoglobin levels in the three children treated. No side-effects were recorded during the administration of either agent. Granulocyte-colony stimulating factor and erythropoietin appear to be safe and useful agents in the management of HIV-infected children.

scholarly journals Inhibition of Human Immunodeficiency Virus-1 (HIV-1) Replication After Transduction of Granulocyte Colony-Stimulating Factor–Mobilized CD34+ Cells From HIV-1–Infected Donors Using Retroviral Vectors Containing Anti–HIV-1 Genes

Blood ◽  
1997 ◽  
Vol 89 (7) ◽  
pp. 2259-2267 ◽  
Author(s):  
Gerhard Bauer ◽  
Penelope Valdez ◽  
Karen Kearns ◽  
Ingrid Bahner ◽  
Sui Fang Wen ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Retroviral Vectors ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Cd34 Cells ◽  
Immunodeficiency Virus ◽  
Anti Hiv ◽  
Stimulating Factor ◽  
Hiv 1 ◽  
Human Immunodeficiency Virus 1

Abstract Transfer of “anti-HIV-1 genes” into hematopoietic stem cells of human immunodeficiency virus-1 (HIV-1)–infected individuals may be a potent therapeutic approach to render mature cells arising from transduced stem cells resistant to the destructive events associated with HIV-1 infection. To determine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals already infected with HIV-1, granulocyte colony-stimulating factor mobilized peripheral blood CD34+ cells were isolated from HIV-1–infected individuals and transduced with retroviral vectors containing three different anti–HIV-1-genes: the Rev binding domain of the Rev Responsive Element (RRE decoy) (L-RRE-neo), a double hammerhead ribozyme vector targeted to cleave the tat and rev transcripts (L-TR/TAT-neo), and the trans-dominant mutant of rev (M10) (L-M10-SN). As a control, a vector mediating only neomycin resistance (LN) was used. After 3 days of transduction on allogeneic stroma in the presence of stem cell factor, interleukin-6 (IL-6), and IL-3, the cultures were G418-selected, and then challenged with HIV-1JR-FL and a primary HIV-1 isolate. Compared with the control cultures, the L-RRE-neo–, L-TR/TAT-neo–, and L-M10-SN–transduced cultures displayed up to 1,000-fold inhibition of HIV-1 replication after challenge with HIV-1JR-FL and the primary HIV-1 isolate. Growth of the hematopoietic cells in long-term bone marrow culture was not perturbed by the presence of any of the anti–HIV-1 genes. This study shows that anti–HIV-1 genes can be introduced into CD34+ cells from individuals already infected with HIV-1, and strongly inhibit HIV-1 replication in primary monocytes derived from the CD34+ progenitors.

Sign in / Sign up

Export Citation Format

Share Document